The company seeks to realign its field sales force to more aggressively preserve the its financial resources while maintaining sales coverage of the physicians with the highest potential to prescribe Moxatag tablets, 775mg.
In addition, the company has also reduced its corporate staff by approximately 20%. As a result of these cost-saving measures, MiddleBrook expects to achieve approximately $15 million in annualized savings.
John Thievon, MiddleBrook's president and CEO, said: "Our field sales force territory realignment is based on cumulative Moxatag prescription data and will allow us to concentrate our resources in markets where we have best demonstrated prescription volume access. We continue to seek opportunities to co-promote, in-license or acquire another product to further utilize our nationwide field sales force more effectively."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index